Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities

被引：0
|
作者：
Alan Menter
Gerald G. Krueger
So Yeon Paek
Dario Kivelevitch
Iannis E. Adamopoulos
Richard G. Langley
机构：
[1] Baylor Scott & White,Division of Rheumatology, Allergy and Clinical Immunology
[2] University of Utah,undefined
[3] University of California at Davis,undefined
[4] Dalhousie University,undefined
来源：
Dermatology and Therapy | 2021年 / 11卷
关键词：
Comorbidities; Cytokines; Inflammation; Interleukin-17; Interleukin-23; Psoriasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Psoriasis is an immune-mediated inflammatory skin disease associated with numerous inflammatory comorbidities, including increased cardiovascular risk. The interleukin (IL)-23/IL-17 axis plays a central role in the immunopathogenesis of psoriasis and related comorbidities by acting to stimulate keratinocyte hyperproliferation and feed-forwarding circuits of perpetual T cell-mediated inflammation. IL-17 plays an important role in the downstream portion of the psoriatic inflammatory cascade. This review discusses the distinct mechanisms of action of IL-17 and IL-23 in the immunopathogenesis of psoriasis and related comorbidities plus the significant therapeutic benefits of selectively inhibiting these cytokines in patients with moderate to severe plaque psoriasis.
引用
下载
收藏
页码：385 / 400
页数：15
相关论文
共 50 条
  • [1] Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
    Menter, Alan
    Krueger, Gerald G.
    Paek, So Yeon
    Kivelevitch, Dario
    Adamopoulos, Iannis E.
    Langley, Richard G.
    DERMATOLOGY AND THERAPY, 2021, 11 (02) : 385 - 400
  • [2] Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis
    Egeberg, A.
    Andersen, Y. M. F.
    Halling-Overgaard, A-S
    Alignahi, F.
    Thyssen, J. P.
    Burge, R.
    Mallbris, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (01) : 39 - 46
  • [3] Interleukin-17, interleukin-23, and psoriasis: Current prospects
    Mudigonda, Parvathi
    Feneran, Ashley
    Feldman, Steven
    Mudigonda, Tejaswi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB195 - AB195
  • [4] The interleukin-23/interleukin-17 Axis Links Adaptive and innate immunity in Psoriasis
    Schoen, Michael P.
    Erpenbeck, Luise
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [5] Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis (vol 34, pg 39, 2020)
    Egeberg, A.
    Andersen, Y. M. F.
    Halling-Overgaard, A. -S.
    Alinaghi, F.
    Thyssen, J. P.
    Burge, R.
    Mallbris, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (09) : 2156 - 2156
  • [6] The Interleukin-23/Interleukin-17 axis in intestinal inflammation
    Maloy, Kevin J.
    JOURNAL OF INTERNAL MEDICINE, 2008, 263 (06) : 584 - 590
  • [7] Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis
    Shen, H.
    Xia, L.
    Lu, J.
    Xiao, W.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2011, 40 (03) : 217 - 220
  • [8] Interleukin-17 and interleukin-23 regulate Langerhans cell migration
    Eaton, L. H.
    Dearman, R. J.
    Kimber, I.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (03) : 622 - 624
  • [9] Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis
    Zeyu Chen
    Yu Gong
    Yuling Shi
    Clinical Drug Investigation, 2017, 37 : 891 - 899
  • [10] Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis
    Chen, Zeyu
    Gong, Yu
    Shi, Yuling
    CLINICAL DRUG INVESTIGATION, 2017, 37 (10) : 891 - 899
12345